Advancing patient care through molecular diagnostic testing

Interpace Diagnostics develops molecular diagnostic tests. You can be assured that all of the molecular tests we offer are driven by rigorous, validated science.

We power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. The unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis.

Interpace Diagnostic Molecular Tests


ThyGenX® Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier molecular testing that aids in the diagnosis of thyroid nodules by identifying genetic alterations associated with thyroid cancer

I am a physician
I am a patient


PancraGen™ molecular diagnostic testing that determines cancer risk in pancreatic cysts

I am a physician
I am a patient

Looking Toward the Future of Molecular Diagnostics

We constantly explore areas for the future, invest in research and partnerships, seek opportunities to expand our molecular diagnostics capabilities and serve additional unmet needs in molecular diagnostic testing.

Coming soon… BarreGEN™

Barrett’s Esophagus


Molecular diagnostic test to determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus

In the pipeline…

Pancreatobiliary Cancer


Late-stage development of a test to assess pancreatobiliary cancer risk by testing tissue taken from biliary stricture brushings


Interpace Diagnostics Group Begins Trading on NASDAQ

PARSIPPANY, N.J., Dec. 23, 2015 /PRNewswire/ — Interpace Diagnostics Group, (Nasdaq: IDXG) has announced that it will begin trading today on the NASDAQ under the ticker symbol “IDXG”. […]

Press Release: PancraGEN Medicare Coverage

Interpace Diagnostics Announces Continued Medicare Coverage for PancraGEN™ Pancreatic Cyst Risk Classifier Test […]

Press Release: ThyGenX® and ThyraMIR™

Interpace Diagnostics Announces New Data Further Validating the Power of the Combination of its Molecular Diagnostic Thyroid Tests ThyGenX® and ThyraMIR™Cytology Testing to be Added to Fine Needle Aspiration Testing […]

Press Release: PancraGEN™

Interpace Diagnostics Announces New Analyses Showing Positive Impact of PancraGEN™ in the Clinical Management of Pancreatic Cysts […]

Press Release: Additional Coverage for Thyroid and Pancreas Tests

ThyGenX™ and ThyraMIR™ Gain Coverage with Large Regional PayerPancraGen™ Contracted Coverage Extended Among National and Key Regional Payers […]